Disparities in Hepatitis C Among People Aged 12-59 With no History of Injection Drug Use, United States, January 2013-March 2020.

Details

• Alternative Title:
  Liver International: Official Journal of the International Association for the Study of the Liver, 2024, v. 44, no. 12: Disparities in Hepatitis C Among People Aged 12-59 With no History of Injection Drug Use, United States, January 2013-March 2020.
• Journal Article:
  Liver International: Official Journal of the International Association for the Study of the Liver
• Personal Author:
  Ly, Kathleen N. ; Barker, Laurie K. ; Kilmer, Greta ; Shing, Jaimie Z. ; Jiles, Ruth B. ; Teshale, Eyasu
• Description:
  In the United States, hepatitis C virus (HCV) infection occurs primarily through injection drug use (IDU), but transmission also occurs through other ways. This study examined HCV prevalence and disparities among US residents aged 12-59 years with no IDU history.
  
  We analysed 2013-March 2020 National Health and Nutrition Examination Survey data to calculate the HCV prevalence among people with no drug use history and only a non-IDU history, collectively referred to as no IDU history. These estimates were compared to those with an IDU history and stratified by sociodemographic and hepatitis A and hepatitis B serologic characteristics.
  
  The current HCV infection prevalence among people aged 12-59 was .7% overall, and specifically 17.2% among people with an IDU history, .9% among people with a non-IDU history and .2% among people with no drug use history. These rates represented 1.4 million people with current HCV infection, of whom, 730 000 had an IDU history, 262 000 had a non-IDU history and 309 000 had no drug use history. Among people with no drug use history, current HCV infection prevalence was higher for people born during 1954-1965 versus after 1965, had completed high school or less versus at least some college and had past/present hepatitis B versus vaccinated for hepatitis B.
  
  While the HCV infection burden was highest among people with an IDU history, we found a sizeable burden among people without such a history. These findings support policies and practices aimed at addressing disparities among people needing treatment.
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Adolescent
  • Male
  • Female
  • Prevalence
  • Adult
  • Child
  • Young Adult
  • Middle Aged
  • Substance Abuse, Intravenous
  More +
• Keywords:
  • disparities
  • HCV
  • hepatitis C
  • non-traditional risk factors
  • prevalence
• Source:
  Liver International: Official Journal of the International Association for the Study of the Liver, 2024, v. 44, no. 12
• DOI:
  https://doi.org/10.1111/liv.16108
• ISSN:
  1478-3223 ; 1478-3231
• Pubmed ID:
  39324414
• Pubmed Central ID:
  PMC11927374
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  3250-3259 (19 pdf pages)
• Volume:
  44
• Issue:
  12
• Download URL:
  https://stacks.cdc.gov/view/cdc/262006/cdc_262006_DS1.pdf
• File Type:
  [PDF - 619.50 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:679e7cb506bf2140f4de28992ff3bebba05ea86b3518f3849a07ac0942f26612a82d1529fc7c43184a77990ce9a60b0c1afcfdc82d9ac550c1032b042d579f3c